Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R.J. Israel
Impact of Previous Biologic Use on Efficacy and Safety of Brodalumab and Ustekinumab in Patients With Moderate-To-Severe Plaque Psoriasis: Integrated Analysis of AMAGINE-2 and AMAGINE-3
British Journal of Dermatology
Dermatology
Medicine
Related publications
Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States
Dermatology and Therapy
Dermatology
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
JAMA Dermatology
Dermatology
Medicine
Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial
Journal of the American Academy of Dermatology
Dermatology
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis
Clinical pharmacology and therapy
